๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hematologic Malignancy
Clinical trial register · China

Hematologic Malignancy Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 4 Hangzhou 3 Wuhan 2 Beijing 2 Xiamen 1
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai4 Hangzhou3 Wuhan2 Beijing2 Xiamen1
All 6 locations
Target enrolment
to

Hematologic Malignancy trials in China

11 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
CD45RA-depleted DLI for the Prevention of Viral Infections in High-risk Patients After Haploidentical Transplantation
NCT07672964Hematologic Malignancy, Haplo-identical HCT
Ruijin Hospital
Phase 1
30
Shanghai
2026-07-01
Recruiting
Clinical Study of the Safety and Efficacy of Allogeneic TCR-enhanced Vฮด2 T Cell in Patients With Malignant Tumors.
NCT07570563Hematologic Malignancy, Solid Tumor
Chinese PLA General Hospital
Phase 1/2
24
Beijing
2026-06-05
Recruiting
CD45RA-depleted DLI for the Treatment of Refractory/Persistent Viral Infections After Haploidentical Transplantation
NCT07662369Hematologic Malignancy, Haplo-identical HCT
Ruijin Hospital
Phase 1/2
30
Shanghai
2026-06-01
Recruiting
Comparing the Efficacy of Different Durations of Maribavir Treatment Regimens in Allo-HSCT
NCT07511127Hematologic Malignancy
Ruijin Hospital
Phase 3
218
Shanghai
2026-02-28
Recruiting
T-cell Developmental Status in Patients With Malignant Hematological Tumors
NCT07035938Hematologic Malignancy
The First Affiliated Hospital of Xiamen University
Observational
75
Xiamen
2025-06-22
Recruiting
CD7-specific CAR-T Cell in the Treatment of CD7-positive Relapsed/Refractory Hematologic Tumors
NCT06720324Hematologic Malignancy
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1/2
80
Wuhan
2024-12-31
Recruiting
Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia
NCT07014449AML (Acute Myelogenous Leukemia, Relapsed Acute Myelogenous Leukemia, Refractory Acute Myeloid Leukemia, Hematologic Malignancy
Hangzhou Weben Pharma Co., Ltd
Phase 1
18
Hangzhou
2024-11-03
Recruiting
TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies
NCT06484816Non Small Cell Lung Cancer, Advanced Solid Tumor, Hematologic Malignancy
Shenzhen TargetRx Co., Ltd.
Phase 1
90
Hangzhou
2024-07-08
Active, closed
CMV-specific T Cell Immunity Test Indicated Prophylaxis of Letermovir After All-HSCT
NCT06449586Hematologic Malignancy
Ruijin Hospital
Phase 3
250
Wuhan, Shanghai, Hangzhou
2024-07-01
Recruiting
TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies
NCT06206174Hematologic Malignancy, Non Hodgkin Lymphoma, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Adult
Shenzhen TargetRx Co., Ltd.
Phase 1/2
30
Tianjin
2024-03-06
Active, closed
Mechanism and Immune Function Analysis of SARS-CoV-2 Infection in Hematologic Tumors
NCT05683353SARS-CoV-2 Infection, Hematologic Malignancy
Peking University First Hospital
Observational
60
Beijing
2022-12-14
Rows per page Showing 1–11 of 11
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/condition/hematologic-malignancy

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 11 of those studies listing the condition Hematologic Malignancy.

How many Hematologic Malignancy trials are recruiting in China?

8 of the 11 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 1 have not yet opened recruitment, 2 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Hematologic Malignancy), 11 studies
PhaseStudiesRecruitingShare
Phase 1/24436.4%
Phase 13227.3%
Observational2118.2%
Phase 32118.2%

Most active sponsors

Lead sponsors with the most studies (Hematologic Malignancy)
Lead sponsorStudiesRecruiting
Ruijin Hospital42
Shenzhen TargetRx Co., Ltd.22
Chinese PLA General Hospital11
Hangzhou Weben Pharma Co., Ltd11
Peking University First Hospital10
The First Affiliated Hospital of Xiamen University11
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.